Search Results - "Introna M"

This result is not displayed to guests.
Login for full access.

Rapid and massive expansion of cord blood-derived cytokine-induced killer cells: an innovative proposal for the treatment of leukemia relapse after cord blood transplantation.

Authors: Introna, M. Franceschetti, M. Ciocca, A. et al.

Source: Bone Marrow Transplantation. Nov2006, Vol. 38 Issue 9, p621-627. 7p. 2 Charts, 3 Graphs.

How can oncogenic transcription factors cause cancer: a critical review of the myb story.

Authors: Introna, M Golay, J

Source: Leukemia (08876924). Sep99, Vol. 13 Issue 9, p1301-1306. 6p.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

P14-32: Toxicity of real-world subway emissions in an ALI exposure model.

Authors: Introna, M. Juárez Facio, A.T. Steimer, S.S. et al.

Source: Toxicology Letters. 2023 Supplement 1, Vol. 384, pS177-S178. 2p.

This result is not displayed to guests.
Login for full access.

Cytokine Induced Killer (CIK) cells for the treatment of haematological neoplasms.

Authors: Introna, M. Golay, J. Rambaldi, A.

Source: Immunology Letters. Sep2013, Vol. 155 Issue 1/2, p27-30. 4p.

This result is not displayed to guests.
Login for full access.

Natural killer cells in intravenous drug abusers with lymphadenopathy syndrome.

Authors: Poli, G. Introna, M. Zanaboni, F. et al.

Source: Clinical & Experimental Immunology. Oct1985, Vol. 62 Issue 1, p128-135. 8p.

Cell-based strategies to manage leukemia relapse: efficacy and feasibility of immunotherapy approaches.

Authors: Rambaldi, A Biagi, E Bonini, C et al.

Source: Leukemia (08876924). Jan2015, Vol. 29 Issue 1, p1-10. 10p.

Mesenchymal stromal cells for the treatment of graft-versus-host disease: understanding the in vivo biological effect through patient immune monitoring.

Authors: Dander, E Lucchini, G Vinci, P et al.

Source: Leukemia (08876924). Jul2012, Vol. 26 Issue 7, p1681-1684. 4p. 1 Chart, 1 Graph.

The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2^V617F.

Authors: Guerini, V. Barbui, V. Spinelli, O. et al.

Source: Leukemia (08876924). Apr2008, Vol. 22 Issue 4, p740-747. 8p. 2 Black and White Photographs, 3 Graphs.

Human platelet lysate allows expansion and clinical grade production of mesenchymal stromal cells from small samples of bone marrow aspirates or marrow filter washouts.

Authors: Capelli, C. Domenghini, M. Borleri, G. et al.

Source: Bone Marrow Transplantation. Oct2007, Vol. 40 Issue 8, p785-791. 7p. 3 Charts, 4 Graphs.

The histone deacetylase inhibitor ITF2357 has anti-leukemic activity in vitro and in vivo and inhibits IL-6 and VEGF production by stromal cells.

Authors: Golay, J. Cuppini, L. Leoni, F. et al.

Source: Leukemia (08876924). Sep2007, Vol. 21 Issue 9, p1892-1900. 9p. 1 Chart, 7 Graphs.

Modulation of cell cycle by graded expression of MLL-AF4 fusion oncoprotein.

Authors: Caslini, C. Serna, A. Rossi, V. et al.

Source: Leukemia (08876924). Jun2004, Vol. 18 Issue 6, p1064-1071. 8p.

Functional transfer of CD40L gene in human B-cell precursor ALL blasts by second-generation SIN lentivectors.

Authors: Bonamino, M. Serafini, M. D'Amico, G. et al.

Source: Gene Therapy. Jan2004, Vol. 11 Issue 1, p85-93. 9p.

Isolation and characterization of the human A-myb promoter: regulation by NF-Y and Sp1.

Authors: Facchinetti, V Lopa, R Spreafico, F et al.

Source: Oncogene. 8/10/2000, Vol. 19 Issue 34, p3931. 10p.

Expression and production of the long pentraxin PTX3 in rheumatoid arthritis (RA).

Authors: Luchetti, M.M. Piccinini, G. Mantovani, A. et al.

Source: Clinical & Experimental Immunology. Jan2000, Vol. 119 Issue 1, p196. 7p. 14 Black and White Photographs, 3 Graphs.

Clinical grade expansion of MSCs.

Authors: Capelli, C. Pedrini, O. Valgardsdottir, R. et al.

Source: Immunology Letters. Dec2015, Vol. 168 Issue 2, p222-227. 6p.